Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Tandospirone (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Acronyms TACGAD
- Sponsors Sumitomo Dainippon Pharma
- 13 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
- 13 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
- 20 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017 as reported by ClinicalTrials.gov.